 Sierra Oncology Inc. NASDAQ: SRRA shares are up 50 after the company announced a term loan deal with Oxford Finance LLC and the release of positive topline results from the vital Phase III MOMENTUM study. The MOMENTUM study, a global double-blind, randomized trial, evaluated momelotinib in treating patients with myelofibrosis that are anemic and symptomatic ... La notizia Sierra Oncology surges 50, here is the catalyst era stato segnalata su Invezz. 